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AbstrAct
The use of neuromodulation as a treatment for major depressive disorder (MDD) has 
recently attracted renewed interest due to development of other non-pharmacological 
therapies besides electroconvulsive therapy (ECT) such as transcranial magnetic stimulation 
(TMS), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), and 
vagus nerve stimulation (VNS). Method: We convened a working group of researchers to 
discuss the updates and key challenges of neuromodulation use for the treatment of MDD. 
results: The state-of-art of neuromodulation techniques was reviewed and discussed in four 
sections: [1] epidemiology and pathophysiology of MDD; [2] a comprehensive overview of 
the neuromodulation techniques; [3] using neuromodulation techniques in MDD associated 
with non-psychiatric conditions; [4] the main challenges of neuromodulation research 
and alternatives to overcome them. Discussion: ECT is the first-line treatment for severe 
depression. TMS and tDCS are strategies with a relative benign profile of side effects; 
however, while TMS effects are comparable to antidepressant drugs for treating MDD; 
further research is needed to establish the role of tDCS. DBS and VNS are invasive strategies 
with a possible role in treatment-resistant depression. In summary, MDD is a chronic and 
incapacitating condition with a high prevalence; therefore clinicians should consider all 
the treatment options including invasive and non-invasive neuromodulation approaches.
Key words: comprehensive review, major depressive disorder, ECT, TMS, clinical guidelines.
Estratégias de neuromodulação para o tratamento da depressão maior: desafios e 
recomendações de uma força-tarefa
rEsuMo
O uso de técnicas de neuromodulação para o tratamento do transtorno depressivo maior 
(TDM) tem despertado um renovado interesse nos últimos anos com o desenvolvimento 
de outras intervenções não-farmacólogicas além da eletroconvulsoterapia (ECT), como 
a estimulação magnética transcraniana (EMT), a estimulação transcraniana por corrente 
continua (ETCC), a estimulação cerebral profunda (DBS) e a estimulação de nervo vago (VNS). 
Método: Nós organizamos um grupo de trabalho com vários pesquisadores para discutir 
os avanços recentes e os principais desafios para o uso da neuromodulação no tratamento 
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do TDM. resultados: O estado-da-arte da neuromodulação foi revisado e discutido em 
quatro seções: [1] epidemiologia e fisiopatologia do TDM; [2] uma revisão das técnicas 
de neuromodulação; [3] o uso das técnicas de neuromodulação na depressão que ocorre 
associada ou em virtude de condições não-psiquiátricas; [4] os principais desafios da 
pesquisa na neuromodulação e alternativas para superá-los. Discussão: ECT é o tratamento 
de primeira linha para depressão grave. EMT e ETCC são estratégias com um perfil 
benigno de efeitos adversos; contudo, enquanto os efeitos da EMT são comparáveis ao 
das drogas antidepressivas para o tratamento da TDM, a eficácia da ETCC ainda precisa 
ser estabelecida por mais pesquisas clínicas. DBS e VNS são intervenções invasivas com 
um papel possível para a depressão refratária. Em resumo, TDM é uma condição crônica, 
incapacitante e de alta prevalência; portanto na prática clínica todas as opções de tratamento 
possíveis, incluindo as farmacológicas e não-farmacológicas, devem ser consideradas. 
Palavras-chave: artigo de revisão, transtorno depressivo maior, eletroconvulsoterapia, 
estimulação magnética transcraniana, recomendações para a prática clínica.
IntroductIon
Although the field of neuromodulation with electro-
magnetic stimulation is not new - dating back to the be-
ginning of the last century with electroconvulsive ther-
apy (ECT), followed by the invasive techniques such as 
deep brain stimulation in the 1960s - it recently attract-
ed further interest due to development of novel methods 
of noninvasive brain stimulation such as repetitive tran-
scranial magnetic stimulation (rTMS) and transcranial 
direct current stimulation (tDCS). Techniques of neuro-
modulation have been tested for a variety of neuropsychi-
atric conditions such as major depression, schizophrenia, 
stroke, chronic pain and Parkinson’s disease. To date, the 
condition that was most studied on this field is major de-
pressive disorder (MDD). 
The development of alternative non-pharmacologi-
cal methods of treatment for MDD is essential as this dis-
order has a high lifetime prevalence (between 8-16%)1,2 
and is challenging to treat as many patients fail to achieve 
complete remission of symptoms or have moderate to se-
vere adverse effects with antidepressants. Therefore, up-
dated guidelines for diagnosing and treating depression 
are needed. 
Specific guidelines from different countries, such as 
Canada3, the UK4; the US5 and Brazil6, have been pub-
lished. In fact, novel treatments need to be regularly up-
dated and incorporated to the therapeutic arsenal of the 
physician, such as neuromodulation therapies. We there-
fore convened a working group of established clinical re-
searchers in major depression and experts in techniques 
of neuromodulation on August 18th, 2009 to discuss the 
updates and main challenges of neuromodulation use for 
the treatment of major depression. In this article we [I] 
summarize the state-of-art of neuromodulation therapies, 
focusing on pathophysiology, efficacy, safety and tolera-
bility; [II] discuss opportunities of using such therapies in 
relatively unexplored contexts of major depression and; 
[III] critically discuss the main challenges and future di-
rections of brain stimulation. 
Method
A task force meeting was set with active researchers 
in the fields of major depression and/or neurostimula-
tion therapies at the Universidade Presbitariana Macken-
zie, in São Paulo, Brazil, in August 18th, 2009. Participants 
from the working group were asked to previously submit 
material to the working group coordinator (FF). During 
the consensus meeting each participant presented his/her 
designated topics with input and discussion by all work-
Table 1. Epidemiology and prevalence of major depressive disorder 
(MDD) in different settings and populations.
Life-time prevalence of MDD 6-12%
Annual prevalence of MDD 3-11%
Relapse rate of the first depressive episode 80%
Response rate after two antidepressant trials 73%
Remission rate after two antidepressant trials 47%
Incidence of treatment-resistant depression 33%
Prevalence of pediatric and juvenile depression 8.7%
Prevalence of geriatric depression 22%
Prevalence of postnatal depression 20.7%
Prevalence of depression in somatic diseases
Prevalence of depression in hospitalized patients 26%
Prevalence of depression in Alzheimer’s disease 11%
Prevalence of depression in HIV/AIDS 12%
Prevalence of depression in heart disease 17%
Prevalence of post-stroke depression 33%
Prevalence of post-MI depression 25%
Prevalence of depression in diabetes 27%
Prevalence of depression in cancer 42%
Prevalence of depression in Parkinson’s disease 51%
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ing group participants. The meeting lasted 3 hours and 
was video-recorded. After the initial meeting, the first au-
thor (ARB) added the suggestions to the initial drafts and 
prepared a preliminary manuscript that was initially edit-
ed by the last author (FF) and then reviewed, edited and 
rectified by each co-author. 
The present paper is divided in four sections: the first 
one overviews the epidemiology and pathophysiology of 
major depression; the second discusses the mechanisms 
of action and the clinical evidence of using each neuro-
modulation technique; the third section considers using 
neuromodulation therapies in other clinical and neuro-
logical contexts in which MDD as a comorbidity is com-
mon; finally, in the fourth section we discuss current chal-
lenges of neuromodulation research and alternatives to 
overcome them. One key consideration here is that the 
rTMS section is the longest due to the large number of 
studies in this area as compared to other techniques ex-
cept ECT - that was less explored due to the fact that 
there are excellent reviews in this area and is an already 
established treatment for MDD with specific guidelines. 
Major depressive disorder
Epidemiology
MDD is a common condition that is widely frequent 
in population: community-baseed surveys conducted in 
several countries using ICD-10 criteria showed a lifetime 
prevalence ranging from 6-12%, with an annual preva-
lence of 3-11%1,2,6,7. Current data show that MDD is an 
incapacitating condition: it is predicted that MDD will 
be the second cause of incapacitating disease in 20208. In 
addition, depression is a chronic, recurrent disorder, as 
nearly 80% of patients relapse after the treatment of an 
episode4. Finally, about one third of patients have treat-
ment-resistant depression (TRD), which is defined as the 
failure to achieve adequate response of symptoms after 
two or more antidepressant treatment trials9,10. In fact, the 
high prevalence of TRD, associated with failure to antide-
pressant response, is an important concern when manag-
ing major depression.
In this context, the National Institute of Mental 
Health (NIMH) sponsored the Sequenced Treatment Al-
ternatives to Relieve Depression trial. STAR*D confirmed 
that the cumulative response and remission rates after 
two failed antidepressant treatments are 73% and 47%, 
respectively11,12. After four failed treatments, response 
and remission rates decay to 19% and 13%11. STAR*D con-
firmed the need for developing novel therapeutic strate-
gies when patients fail to respond to antidepressants. 
In Brazil, Andrade and colleagues2 observed a life-
time prevalence and an annual incidence of depression 
of 16.8% and 7.1%, respectively, in a catchment area of 
two boroughs in São Paulo; while Almeida-Filho et al.13 
observed an annual incidence of 12% in an urban sample 
of Bahia. In 2003, a larger survey conducted by the World 
Health Survey showed a 15% of 30-day prevalence of de-
pression14 in Brazil. The prevalence of major depression 
in Brazil is likely to be similar to other countries2,15. Oth-
er studies showed, in Brazil, the prevalence of acute de-
pressive disorder in pediatric patients, geriatric patients 
and in the postnatal period to be 8.7%, 22% and 20.7%, 
respectively16-18.
Finally, there is a high association between MDD and 
other psychiatric disorders, especially anxiety disorders, 
impulse control disorders and substance use/abuse dis-
orders1, as well as with chronic medical illnesses - for 
instance, the prevalence of MDD in emergency depart-
ments in Latin America ranges from 23 to 35%19; while it 
has been detected on average in 26% in hospitalized pa-
tients20. These numbers confirm the need to develop nov-
el therapeutic strategies for MDD in order to offer alter-
natives to patients who fail to antidepressants or those 
who have contraindication to these drugs.
Pathophysiology 
There are several hypotheses to explain the pathophys-
iology of depression. It is important to review the mecha-
nisms underlying MDD in order to understand the mech-
anisms of action of neuromodulation techniques. 
One important and usually highly cited hypothesis of 
MDD is the “monoamine hypothesis”. The development 
of antidepressant drugs in the 1960s and the following 
finding that such drugs had synaptic activity in circuits 
controlled by the neurotransmitters norepinephrine, do-
pamine and serotonin led to the “monoamine hypothesis” 
which suggests that MDD symptoms are related to low 
concentrations of monoamines in the synaptic cleft21. Al-
though such view generally agrees with the pharmacolog-
ical activity of antidepressant drugs (e.g. MAO inhibitors 
act by stopping monoamine metabolism in the pre-synap-
tic neuron; while serotonin selective reuptake inhibitors 
act by increasing serotonin concentration at the synap-
tic site), it is not sufficient to explain other observations 
- for example, the time lag of antidepressants for thera-
peutic action, and that symptoms of MDD do not direct-
ly relate with monoamine synaptic levels22. Other mech-
anisms need then to be entertained.
One interesting and increasingly discussed hypothesis 
is the neuroplastic hypothesis. Several animal and clinical 
studies showed that the Brain Derived Neurotrophic Fac-
tor (BDNF) serum levels are decreased in patients with 
major depression and normalized after antidepressant 
treatment23. BDNF expression is associated with neuronal 
survival and differentiation24; while lack of BDNF leads 
to neuronal apoptosis25. In addition, BDNF plays a key 
role in long-term potentiation (LTP) - a feature of neu-
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rons to facilitate the synaptic transmission in areas whose 
neurons are constantly demanded (on the other hand, 
low BDNF expression is related to Long-Term Depres-
sion (LTD) - i.e., the slowdown of neuronal activity with 
decreased cortical activity)26. The neurotrophin hypoth-
esis complements the monoamine hypothesis as synap-
tic activity is enhanced when monoamine levels increase 
- and also suggests there is a “final common pathway” of 
different antidepressant treatment modalities that ulti-
mately lead to BDNF levels increasing. If the neuroplas-
tic hypothesis is relevant to MDD, then it can be hypoth-
esized that patients with MDD have decreased plasticity 
that might be accentuated in some neural circuits; there-
fore obstructing the creation of new synapses in areas as-
sociated with positive emotional processing. 
These two previous hypotheses have lead to anoth-
er one: the neural system hypothesis. The advancement 
of neuroimaging techniques showed that specific brain 
areas, such as the amygdala and the hippocampus, have 
a lower volume in depressed patients when compared 
to controls27,28. In addition, functional studies suggest a 
high level of activity in the ventro-medial prefrontal cor-
tex (vmPFC) and a low level of activity in the dorso-later-
al prefrontal cortex (DLPFC). It seems that patients with 
major depression have lower excitability in the left motor 
cortex29, in the left hemisphere30 and a higher brain ac-
tivity in the right cortex31. These findings suggest a “dif-
ferential activity” of certain brain areas in patients with 
MDD, which can explain some symptoms of depres-
sion: for instance, psychomotor retardation and execu-
tive function impairment (related to the DLPFC), feel-
ings of guilt and hopelessness (related to hippocampus 
and amygdala dysfunction), anhedonia (related to nucle-
us accumbens) and negative emotional judgment (relat-
ed to left-right imbalance)32-34.
Another important theory lies in the influence of the 
hypothalamic-pituitary-adrenal (HPA) axis and its main 
end-product (cortisol) in cortical activity. Cortisol recep-
tors are widely distributed in the brain, especially in the 
hippocampus, amygdala and hypothalamus35 - areas that 
are also impaired in MDD. In fact, there is convincing 
evidence from basic and clinical studies of overactivity 
of HPA axis among depressed subjects - e.g., high corti-
sol serum levels in depressed subjects36; and exaggerated 
cortisol increasing after the dexamethasone supression 
test37. Along these lines, recent evidence suggests a mod-
erate role for steroid hormones in the antidepressant ef-
ficacy of TMS; i.e., cortisol and other hormones can im-
pair cortical activity in the brain (especially in those ar-
eas with high levels of steroid receptors) thus leading to 
a more severe, “endogenous” depression38. 
Taken together, the integrated view of these hypothe-
ses supports the notion that MDD is a disorder associat-
ed with dysfunction in critical areas related to mood reg-
ulation. In fact, two major pathways can be determined 
here: the cognitive-executive pathway, in which a hypo-
active DLPFC fails to regulate areas related to executive 
functioning; and the affective-somatic pathway, in which 
a hyperactive vmPFC modulates erratically areas relat-
ed to negative affect and self-awareness39. The rationale 
in using different neurostimulation therapies is based on 
their mechanisms of inhibiting or enhancing activity in 
these pathways, as we discuss below. 
The neurostimulation therapies
Electroconvulsive therapy (ECT)
ECT is the first and most studied brain stimulation 
therapy to date. In fact, Cerletti and Bini, in 1938, con-
ducted the first descriptions of using electric stimuli to 
induce therapeutic seizures40. Although its mechanisms 
of action are still incompletely known, accumulated ev-
idence points that its antidepressants effects are relat-
ed to several mechanisms, such as restoring hemispher-
ic balance41, increasing BDNF serum levels42, enhancing 
neurogenesis through a series of electrical shocks43 and, 
long-term up-regulation of serotonin activity and down-
regulation of muscarinic activity44. Nevertheless, sever-
al guidelines support the role of ECT as a first-line treat-
ment of severe major depressive disorder, especially in 
psychotic and/or suicidal patients, or those with catato-
nia or treatment-resistant depression3,5,6.
In recent years, several systematic reviews and me-
ta-analyses of ECT efficacy have been published45-47. The 
UK ECT Review Group45 reviewed the efficacy of ECT 
vs. simulated (sham) ECT (6 trials, 256 patients), ECT vs. 
drug therapy (18 trials, 1144 subjects), bilateral vs. uni-
lateral (28 trials, 1408 participants), and low vs. high dose 
ECT (7 trials, 342 patients). Compared to sham ECT, ac-
tive ECT was significantly more effective, with a mean 
difference in endpoint Hamilton scores of 9.7 (95% CI 5.7- 
13.5). The pooled analysis of ECT comparisons against 
amitriptyline, imipramine, phenelzine, or others favored 
ECT with a mean Hamilton difference of 5.2 (95% CI 
1.4-8.9). Bilateral ECT was more effective than unilateral 
(mean Hamilton reduction of 3.6 points - 95% CI rang-
ing between 2.2-5.2). Finally, treatment with high dos-
es of ECT led to a greater reduction in depressive symp-
toms with a mean change of Hamilton scores of 4.1 (95% 
CI 2.4-5.9) when compared to placebo. This meta-anal-
ysis did not identify significant differences between brief 
pulse vs. sinewave ECT and ECT delivered two vs. three 
times a week. These results were confirmed by following 
meta-analyses46,47.
The negative cognitive effects of ECT were explored 
by Sackeim et al.48 who performed an observational, nat-
uralistic study with 751 patients who underwent ECT for 
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Table 2. Summary of the neurostimulation methods. 
Method Mechanism of action Efficacy Safety Delivery method(s)
Electroconvulsive 
therapy (ECT)
Potent electric stimuli for in-
ducing therapeutic seizures 
and increasing overall corti-
cal activity.
Several MA showed it is 
strongly effective for severe 
MDD, psychotic MDD, TRD 
and MDD with suicidal ide-
ation.  Several MA showed it 
is superior to simulated ECT 
and antidepressants.
Very low mortality rates, but 
caution with patients with 
cardiovascular disease. Short-
term side effects are head-
ache and myalgia. Long-term 
cognitive impairment is pos-
sible, especially in subgroup 
of patients and in some de-
livery methods.
Pulse vs. Sinewave
Uni- vs. Bilateral
Bifrontal vs. Bitemporal
2 vs. 3 times/week
Repetitive 
transcranial 
magnetic 
stimulation (rTMS)
Use of electromagnetic in-
duction to focus induced 
current in brain; repetitive 
TMS modulates long-term 
cortical excitability.
Recent MA showed it is as 
effective as antidepressant 
drugs in treating MDD and 
TRD (indirect comparison). 
One RCT showed rTMS and 
venlafaxine ER to have sim-
ilar efficacy. One subgroup 
analysis suggests that rTMS 
has increased efficacy in TRD 
patients.
Induced seizures are the 
most severe adverse event, 
but only 16 cases were re-
ported hitherto. Common 
side effects include head-
ache and facial pain. No cog-
nitive impairment reported.
High vs. Low frequency
Left vs.Right DLPFC stimulation
80-120% MT
10-30 sessions
Transcranial 
direct current 
stimulation (tDCS)
Weak direct currents are ap-
plied to the brain via scalp 
electrodes in a simple, pain-
less manner; shifting up or 
down the cortical excitabil-
ity according to the current 
polarity.
Mixed results so far (One 
positive and one negative 
RCT, two positive open-la-
bel studies).
No serious adverse events. 
Common side effects in-
clude skin irritation and itch-
ing sensation on the spot of 
stimulation.
Target area: left DLPFC
Reference: right DLPFC or right 
supra-orbital area
1-2 mA / 15-30 min
5-10 sessions
Deep brain 
stimulation (DBS)
Electrodes connected to 
pulse generators are im-
planted in some brain areas, 
the most studied is the sub-
genual cingulate region.
There are only open trials 
with small samples to date, 
studying patients with high 
degree of refractoriness and 
showing response rates of 
50-60%.
Invasive brain stimulation 
procedure with the usu-
al risks of a neurosurgical 
procedure. Long-term ad-
verse events include trem-
or and transient hypomania. 
No cognitive impairment re-
ported.
Parameters of stimulation are 
adjusted individually.
Vagus nerve 
stimulation (VNS)
Electrodes connected to 
the left vagus nerve gener-
ate impulses further trans-
mitted to subcortical areas.
Only one RCT, with incon-
clusive results. Open-label 
studies show favorable re-
sults. FDA-approved for pa-
tients who failed +4 antide-
pressant treatments.
Usual risks of a head & neck 
surgery. Transient hypoma-
nia reported. No cognitive 
impairment reported.
Parameters of stimulation are 
adjusted individually.
MA: meta-analysis; MDD: major depressive disorder; TRD: treatment-resistant depression.
MDD. These patients went through a comprehensive neu-
ropsychological battery at pre-ECT (baseline), after com-
pleting ECT (post-ECT) and at 6-month follow-up, which 
measured cognitive status, psychomotor function, atten-
tion, and several aspects of memory. They observed an 
important decrease in performance in almost all neurop-
sychological tests at post-ECT. At 6-month follow-up, pa-
tients treated with sine wave stimulation continued to 
have slower reaction times; while those treated with bi-
lateral ECT had inferior performance on the global cog-
nitive status, reaction time, Stroop effect and some mem-
ory tasks. Multi-linear regressions showed that bilater-
al ECT, sine wave ECT, older age, lower premorbid cog-
nitive function, and female gender were associated with 
greater cognitive effects. 
In summary, despite being a very effective treatment 
for MDD, ECT is also associated with important cogni-
tive deficits, especially in subgroups of patients and in 
specific protocols. 
Repetitive transcranial magnetic stimulation (rTMS)
Mechanisms of action
TMS uses the principle of electromagnetic induction 
to focus induced current in the brain49. When applied 
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transiently, the effects last only a few minutes; howev-
er, when applied repetitively, rTMS (repetitive TMS) can 
modulate cortical excitability for several minutes beyond 
the train of stimulation50. There are two types of rTMS ac-
cording to the frequency of stimulation: [1] low-frequen-
cy rTMS (<5 Hz) that is applied over the right DLPFC to 
induce a decrease in cortical excitability, and [2] high-fre-
quency rTMS that is applied on the left DLPC to increase 
cortical excitability. Both approaches induce neuroplastic 
changes in the targeted areas - in fact, it has been suggest-
ed that high-frequency rTMS is associated with LTP and 
low-frequency rTMS with LTD51: Chen and colleagues52 
used a protocol (0.1 Hz for 15 minutes) similar to one that 
induced LTD in cortical slice preparations to stimulate the 
motor cortex of volunteers, showing a decrease in the mo-
tor evoked potential that persisted for several minutes, in 
a LTD-like phenomenon; while a TMS/EEG study showed 
LTP-like changes in EEG activity after high-frequency 
(5Hz) rTMS53. However, there is an important variabili-
ty associated with these effects and in fact subjects might 
respond differently to high and low-frequency rTMS ac-
cording to other factors such as baseline cortical activity54.
Thus, it is hypothesized that high-frequency TMS acts 
by increasing activity in the left DLPFC area, thus ame-
liorating depression symptoms. Low-frequency rTMS, on 
the other hand, might act by modifying interhemispheric 
imbalance - i.e., as MDD might be associated with an im-
balance in prefrontal cortex activity, decreasing the right 
DLPFC activity “releases” left DLPFC, which was being 
inhibited via transcallosal connections55. 
Efficacy of rTMS in acute MDD
RTMS has been tested for several neurological and 
psychiatric conditions, but none has had the same num-
ber of studies and positive results than MDD: in fact, al-
though the first meta-analyses published in 2003 and 2005 
showed that rTMS studies were of low quality to date56,57, 
more recent meta-analyses published in 2007 and 2008 
showed the trial design, as well as other parameters of 
stimulation, improved in five years, and that rTMS had 
the same efficacy of pharmacological drugs for MDD58,59, 
with also similar rates of response and remission rates for 
TRD (25% and 17%), respectively, which interestingly is 
similar to the STAR*D results of 19% and 13%11,60. Cur-
rently, rTMS has been approved for use in Brazil, Cana-
da, Israel, and some European countries and also in the 
US. Here it should be underscored that rTMS was only 
approved in the US to treat patients who failed to respond 
to at least one antidepressant trial as a pivotal rTMS study 
performed in 2007 with 301 patients with various degrees 
of refractoriness showed positive results only after a post-
hoc analysis61; however, a subsequent analysis of patients 
failing to at least one adequate trial found a robust posi-
tive result, with an effect size of 0.83 and a drug-placebo 
difference of 5 points62.
To date, most rTMS trials tested its use as a combina-
tion therapy, i.e., the combination of rTMS with a phar-
macological treatment - usually an antidepressant that 
has failed however not tapered off63. A few studies tested 
the use of rTMS as an accelerating therapy, i.e., the use of 
rTMS to hasten an antidepressant response - in this type 
of trial, active or sham rTMS starts simultaneously with 
a pharmacological treatment - 3 of 4 studies showed that 
the active rTMS fastened drug response. The drugs test-
ed were venlafaxine, escitalopram or sertraline64; amitrip-
tyline65; escitalopram66; mirtazapine or venlafaxine67 - the 
last trial, however, showed a negative response. 
Finally, Bares and colleagues68 compared low-frequen-
cy rTMS vs. venlafaxine ER in TRD patients in a dou-
ble-blind, randomized design, finding that both therapies 
had similar response and remission rates (rTMS: 33% and 
19%, venlafaxine ER: 39% and 23%, respectively) as well 
as drop-out rates. To date, this is the first double-blind-
ed, randomized clinical trial that directly compared rTMS 
against a pharmacological treatment for MDD.
Efficacy of rTMS as a maintenance 
treatment (relapse prevention)
Currently, there is limited data concerning using 
rTMS as a maintenance treatment for MDD. There are 
no randomized, controlled trials assessing rTMS mainte-
nance therapy to prevent relapse as this type of trial would 
have some practical issues as it is not possible to random-
ize patients that received active treatment previously to 
sham treatment without compromising blinding. There-
fore, the efficacy of rTMS as a maintenance treatment is 
better assessed through naturalistic studies. Along these 
lines, Fitzgerald et al.69 followed a sample of 19 patients 
previously treated with rTMS and observed a mean time 
of 10 months for relapsing, and also most of the patients 
were successfully treated with rTMS after relapse. Demir-
tas-Tatlidede et al.70 accompanied 16 medication-free pa-
tients with TRD who responded to rTMS until relapse, 
when they were treated again with rTMS. Importantly, 
these patients continued receiving rTMS weekly or two 
times a week. The authors observed a medication-free pe-
riod ranging from 26-43 months and that approximate-
ly 65% of patients individually sustained a clinically sig-
nificant response to retreatment with rTMS. Finally, Co-
hen and colleagues71 followed 204 patients who remitted 
with rTMS assessing the time to relapse; they observed 
that 75% of patients had relapsed after 6 months of treat-
ment, and a long duration of rTMS effects was negative-
ly associated with age and positively with the number of 
rTMS sessions during acute treatment. 
Thus, although there is little evidence on using rTMS 
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as a maintenance treatment for MDD, initial studies 
showed encouraging results - further studies should as-
sess whether different protocols (e.g. weekly, bi-week-
ly, monthly rTMS applications) are better to sustain re-
sponse without using antidepressant drugs. On the other 
hand, it is important to notice that patients who respond-
ed to a prior rTMS treatment are likely to respond again 
to rTMS whether they relapse.
Safety and tolerability 
Loo and colleagues72 recently reviewed all published 
rTMS trials for side effects. They found that rTMS is a 
treatment virtually absent of serious side effects: in fact, 
only 16 patients presented seizures (the most severe side 
effect reported)- most of them having prior neurological 
disorders or using parameters outside of the recommend-
ed guidelines. In addition, they showed that rTMS did 
not induce cognitive impairments; in fact, some studies 
showed that active groups improved neuropsychological 
assessments. Regarding hearing loss, it has been shown 
that rTMS can transiently increase auditory threshold, 
thus wearing earplugs is recommended. Common side 
effects are headache that responds readily to oral anal-
gesia and facial pain due to muscular twitches. Final-
ly, regarding on treatment-emergent (i.e., during or af-
ter rTMS treatment) mania/hypomania, another meta-
analysis showed that the risk rates are low and similar for 
active (0.84%) and sham (0.73%) groups73. However, 9 of 
13 patients who presented treatment-emergent mania/hy-
pomania were suffering from bipolar depression.
Parameters of stimulation
Several variables should be considered when deliver-
ing rTMS treatment, such as site of stimulation, frequen-
cy of trains, intensity of stimulus, frequency of sessions, 
and duration of treatment. Regarding left vs. right stim-
ulation, the accumulated evidence favors the former as 
more studies were performed stimulating the left DLP-
FC74; and the evidence for low-frequency right DLPFC is 
mixed75-77. However, low-frequency rTMS seems to be 
better tolerated78 and might be an interesting approach in 
selected cases. Considering the frequency of trains, most 
low-frequency protocols use 1 Hz or less; while high-fre-
quency stimulation ranges from 5 to 20 Hz79.80 with more 
recent studies favoring the 10Hz-frequency61,67,81,82. Along 
these lines, although the intensity of stimulus (indexed to 
the motor threshold - MT) can vary from 80-120% MT, 
there is a tendency of more recent studies in using inten-
sities >100%, when compared to the first studies that used 
intensities <100% - perhaps due to safety concerns59.
rTMS is usually delivered daily in weekdays (i.e. 5 ses-
sions per week) although other studies used different pro-
tocols such as three times a week or two times per day83. 
Finally, several studies have shown that a larger number of 
sessions is associated with a better response59,62 as well as 
a larger time period to relapse71. Nevertheless, this num-
ber can range from 10 to 30 sessions (i.e. 2 to 6 weeks, as 
sessions are not usually delivered in weekends). 
Finally, one point that needs to be underscored is that 
parameters of stimulation have not been compared sys-
tematically and they reflect much more the personal de-
cision of the group of researchers conducting the trial; 
therefore readers should consider this carefully when 
choosing the parameters of stimulation in clinical prac-
tice and research. Finally, individual parameters also play 
an important role - for instance, baseline cortical activity, 
medications being used by the patients. These factors can 
have an important interaction with the effects of rTMS.
Table 3. Recent meta-analyses of rTMS efficacy studies.
Author Year Studies Main results Comments
Martin et al.56 2003 14 rTMS was more effective than sham at 2 (SMD= 
–0.35) but not at 4 weeks (SMD= –0.33, p=ns).
The low quality of studies provided insufficient 
evidence for rTMS efficacy.
Couturier et al.57 2005 6 rTMS was not more effective than sham treat-
ment (WMD= –1.1, 95% CI= –4.5-2.3).
Only 6 of potential 21 studies were included; 
all studies were of low quality.
Herrmann and 
Ebmeier170
2006 33 rTMS was more effective than sham, but the 
variability was too great and no significant pre-
dictors were found.
The hypotheses of underpowered studies or 
“nonspecific” TMS effects were raised.
Gross et al.58 2007 5 rTMS was more effective than sham (SMD= 
–0.76; 9% CI –1.01 to –0.51).
The authors concluded rTMS design improved 
in the past 5 years.
Lam et al.60 2008 24 Response and remission rates of active 
rTMS (25% and 17%) were superior to sham 
(9% and 6%).
Only trials that included patients with treat-
ment-resistant depression were selected.
Schutter et al.74 2009 30 rTMS was superior to sham treatment (ES=0.39; 
95% CI 0.25-0.54) and heterogeneity was not 
significant.
The authors concluded the ES of rTMS is com-
parable to antidepressant drugs.
SMD: standardized mean difference; WMD: weighted mean difference; CI: confidence interval; ES: effect size.
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rTMS in depressed patients with bipolar disorder
Although the clinical manifestations of bipolar de-
pression and MDD might be quite similar, recent evi-
dence shows that their clinical management is different, 
as bipolar depression is better managed with either mood 
stabilizers (lithium, anticonvulsants or some atypical an-
tipsychotics) in monotherapy or a combination of mood 
stabilizers and antidepressant drugs (lithium/divalproex 
and selective serotonin reuptake inhibitors)84. Thus, one 
important question is whether rTMS for bipolar depres-
sion is as effective as for MDD. However, there are only a 
few studies on the topic: Nahas and colleagues79 enrolled 
23 patients with bipolar depression; randomizing them 
to receive either high-frequency rTMS or placebo. They 
failed to show difference between groups. Subsequently, 
Dolberg and colleagues85 recruited 20 patients to receive 
active or sham intervention, finding mixed results - al-
though a significant difference was observed at week-2, 
no difference between groups was found at the final end-
point (week-4). In 2004, Cohen et al.86 used low-frequen-
cy rTMS as an adjunctive therapy in refractory bipolar 
depression. In an open-label study, 22 patients received 
15 sessions of rTMS - after 3 weeks, 16 showed response. 
Tamas and colleagues87 compared four patients on active 
rTMS and one on placebo, obtaining a difference between 
groups only at week-6. Finally, in 2009, Dell’Osso and col-
leagues88 performed an open-label study using low-fre-
quency rTMS in 11 patients, showing significant reduc-
tions in all rating scales.
In conclusion, although many initial rTMS controlled 
trials enrolled a few depressed patients with bipolar dis-
order while studying major depressive disorder, the spe-
cific use of rTMS in this condition has been insufficient-
ly explored. Thus, considering the prevalence and sever-
ity of bipolar disorder, further well-designed sham-con-
trolled rTMS studies on this topic are needed.
Cost-effectiveness
A recent study addressed the cost-effectiveness of 
rTMS in major depression: using data from previous 
multi-center studies and of the STAR*D trial, the authors 
modeled the cost-effectiveness of rTMS considering dif-
ferent scenarios in which rTMS was combined to anti-
depressants after one, two or more than two drug tri-
als failure, and comparing such association with different 
augmentation pharmacological strategies (antidepressant 
with mood stabilizers or atypical antipsychotics). Con-
sidering a base cost of US$300 per treatment session for 
rTMS, the authors demonstrated that rTMS is cost-effec-
tive considering QALY criteria and might be more cost-
effective than certain psychopharmacological combina-
tions (especially those combining newer antidepressants 
with mood stabilizers and atypical antipsychotics)89.
Transcranial direct current stimulation
Transcranial direct current stimulation (tDCS) is a re-
newed method of non-invasive brain modulation. It is 
based on a transcranial application of weak direct currents 
(usually up to 2mA) via scalp electrodes in a non-invasive, 
simple and painless manner. Other advantages are the low 
cost of the device and the possibility of a reliable sham 
control. The effects are polarity-dependent: while anod-
al stimulation induces an enhancement on cortical excit-
ability, cathodal stimulation decreases it. These effects are 
explained as related to shifting on membrane resting po-
tential (depolarization or hyperpolarization, respectively). 
Finally, the effects are also related to the stimulated area90.
The investigation on the effects of tDCS as an anti-
depressant therapy dates from the 1960s. However, the 
lack of methodological rigor on some parameters such 
as the target area, current strength, electrode size, ref-
erence electrode position, number of sessions, and du-
ration of each session might explain some contradictory 
findings between the studies. For instance, Arfai et al.91 
did not find significant effects on depression in a ran-
domized, double-blinded, sham controlled study where 
tDCS (i=0.25mA) was applied on frontal cortex with the 
reference on the thigh; on the other hand, Redfearn et 
al.92, in an open pilot study, found a reduction of depres-
sive symptoms after tDCS (i=0.02 to 0.25 mA) over fron-
tal areas with the reference electrode on the knee (for ex-
tended reviews see93 and94). 
This scenario began to change in the last decade with 
new tDCS protocols in which the parameters of stimula-
tion were well-defined. Also, the emergence of other tech-
niques of brain stimulation, such as TMS, allowed a bet-
ter understanding of the effects of tDCS effects on cor-
tical excitability. In the recent years, some randomized, 
double-blinded, sham controlled clinical trials on the ef-
fects of tDCS on depression have been conducted. 
Table 4 summarizes some parameters and the ob-
served effects of each recent protocol. As it can be ob-
served, all recent studies targeted anodal tDCS over the 
left DLPFC. The only difference regarding electrodes 
montage is the position of cathodal electrode. Ferrucci et 
al.95 applied this electrode over the right DLPFC whereas 
the other protocols used it over the contralateral supraor-
bital area. Besides this difference, the protocols differ with 
respect to number of sessions, time and intensity of stim-
ulation current. In addition, patients of each protocol had 
different degrees of depression severity. Still, tDCS had 
antidepressant effects for patients with mild to moder-
ate and for those with severe symptoms. In addition, it 
appears that the effects of repeated sessions of tDCS can 
prolong its therapeutic effects after the end of treatment. 
A critical point to consider is the concomitant use of 
antidepressants - there is a difference between the stud-
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ies in this respect and this may explain differences in rela-
tion to the effect size observed in each study. For instance, 
Nitsche et al.96 found that citalopram increased and pro-
longed the facilitatory effects of anodal tDCS showing 
that further studies should be done investigating the asso-
ciation of antidepressant pharmacotherapy with tDCS.
Finally, all studies showed only mild adverse effects 
and those, in general, were no different from those ob-
served in the control group.
Deep brain stimulation
Although DBS was first developed in the 1950s and 
was initially used for treatment of chronic pain, it has 
been used for MDD only recently97. When using DBS, 
electrodes connected to implantable pulse generators 
(IPG) are implanted in specific brain areas98-100. For indi-
viduals suffering from depression, electrodes may be im-
planted into the following regions of the brain: subtha-
lamic nucleus, internal globus pallidus, ventral internal 
capsule, ventral striatum, or the subgenual cingulate101-104. 
DBS is the most invasive therapy option for treatment-
resistant depression. It was observed in preliminary stud-
ies that in these patients the subgenual region of the cin-
gulate region (Broadmann area 25) is overactive-provid-
ing a rationale for implantation of deep brain stimula-
tion devices with the aim of reducing this increased ac-
tivity as stimulation in DBS has the goal to interrupt lo-
cal activity.
Mayberg et al investigated the use of DBS in 6 patients 
with treatment-resistant depression; specifically, such pa-
tients had failed in four different medication strategies 
and 5 of 6 also to ECT104. After 6 months of treatment, 
four responded to DBS and three had full or almost full 
remission of depressive symptoms; while two patients 
had to have their DBS devices removed due to persistent 
infections104. This group recently published a follow-up 
study of these same 6 patients in which they underwent 
neuropsychological testing at baseline (before surgery), 
3, 6, and 12-months post-surgery105. Cognitive function 
was evaluated and they found that DBS caused minimal 
to no neuropsychological adverse effects105. One inter-
esting aspect of this study is that parameters of stimula-
tion needed to be adjusted individually in order to pro-
vide beneficial results104. 
Because the data is still scarce with this condition, sev-
eral questions then need to be addressed, such as: wheth-
er DBS might be the long-term solution to patients who 
respond to noninvasive brain stimulation or whether it 
will be possible to develop portable techniques of non-
invasive brain stimulation. Another important question 
is how to localize the optimal site of stimulation - and 
whether neuroimaging is enough to localize such area as 
it may vary across patients.
Vagus nerve stimulation (VNS)
VNS was developed relatively recently in the 1990s106-108. 
It works by having an electrode attached from a pacemak-
er implanted on the left side of the chest to the left vagus 
nerve in the neck106,107. Although its mechanism of action 
remains elusive, it has been suggested that impulses from 
the vagus nerve are transmitted to the following regions: 
locus ceruleus, raphe nuclei, and nucleus tractus soliari-
ous, which then project to other regions of the brain, ul-
timately affecting the limbic system109-113. Therefore, this 
may be a less focal method of electrical stimulation. In 
fact, the lack of focality of this technique might be asso-
ciated with the limited clinical results and might favor the 
use of other techniques such as rTMS or DBS. In addition, 
it might also be used in combination with another focal 
method of brain stimulation. Finally, VNS is used inter-
mittently with trains of stimulation 24 hours per day108,114. 
VNS is approved in the US for treating chronic or re-
fractory depression in patients not showing an adequate 
response after four antidepressant treatments. In a re-
cent systematic review, Daban and colleagues115 could 
only identify one randomized clinical study, the others 
being open-label studies and series of cases, i.e., studies 
of lower methodological quality. In fact, the only blinded 
trial was inconclusive. Therefore, VNS may be seen as a 
new promising form of treatment; however the present 
evidence supporting its use is still limited.
Other neurostimulation approaches
Given the remarkable effects of transcranial stimula-
tion with low-intensity constant direct current (tDCS), 
the use of low-intensity non-constant current (alternate 
current or intermittent direct current) may also prove to 
be an attractive option. Non-constant current can be de-
livered with pulses of unidirectional current in rectan-
gular waves (intensity rapidly increased to a certain am-
plitude, held at the peak without change, and then in-
terrupted by zero current) or sinusoidal waves (intensity 
and direction constantly varies as a function of time). In 
fact, non-constant current can be delivered with unidi-
rectional current (in which pulses share the same polari-
ty) or alternating current (in which the pulses of current 
alternate with opposite amplitude). Indeed, pulsed stim-
ulation is the method used for most of brain stimulation 
therapies previously discussed. Of the variety of methods 
of low-intensity non-constant current that have been ex-
plored, here we will discuss the few specific methods of 
AC stimulation that have been shown to have clinical ef-
fects: cranial electrotherapy stimulation (CES), transcu-
taneous electrical stimulation (TCES) with Limoge’s cur-
rent, transcranial electrical stimulation (TES) with Lebe-
dev’s current, and transcranial alternating current stim-
ulation (tACS). 
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Cranial electrotherapy stimulation (CES) is a form of 
AC stimulation that involves the application of current 
to infra- or supra-auricular structures (e.g. the ear lobes, 
mastoid processes, zygomatic arches, or maxillo-occip-
ital junction). CES is a non-standardized and often in-
distinct method of delivering cranial AC stimulation; in-
deed many studies cite the method of stimulation simply 
as “cranial electrotherapy stimulation” without identifying 
the specific site or other parameters of stimulation (e.g. 
duration, current density, intensity, electrode size) calling 
into question existing reviews of this method. Addition-
ally, CES has been suggested to be effective in the treat-
ment of anxiety, depression, stress, and insomnia116, and 
the following parameters of stimulation have been report-
ed: frequency (0.5 Hz to 167 kHz), intensity (100 uA to 
4 mA), duration of stimulation (5 min to up to 6 consec-
utive days). Of note, although alternating current is ap-
plied to the head in these circumstances, the current may 
or may not be delivered directly to the underlying brain 
structures and thus the term “transcranial” may not ap-
ply; we therefore select the term “cranial” AC stimulation 
to include applications of low-intensity AC in this con-
text. Indeed, CES might more accurately be considered a 
form of peripheral nerve stimulation. 
Exploring brain stimulation for treating 
MDD in different contexts
Somatic diseases
The presence of a chronic clinical diseases increas-
es the life-long prevalence of mood disorders from 8.9% 
to 12.9% and the recent prevalence (last 6 months) from 
5.8% to 9.4% - in fact, more severe illnesses are associat-
ed with higher rates of depressive symptoms (Table1), a 
condition referred as “mood disorder due to a general 
medical condition”117. 
Fibromyalgia
Fibromyalgia - a somatic disease characterized by 
chronic widespread pain, allodynia in specific points, 
joint stiffness and fatigue - is highly associated with de-
pression118. There are a few studies using neurostimula-
tion techniques for treating this overlapping depression-
pain condition: Carretero et al.119 reported an improve-
ment in pain and depression after active low-frequency 
rTMS, but such improvement was not statistically differ-
ent than sham rTMS. Passard et al.120 randomized 30 pa-
tients to receive either active or sham rTMS; they were 
able to demonstrate a significant improvement in pain, 
without any positive effect on depression or anxiety. An-
other brain stimulation technique that has been tested 
for this condition was tDCS, Fregni et al.121 reported a 
decreased efficacy of this technique for the treatment of 
depressive symptoms when patients with fibromyalgia 
were compared to those with major depression, suggest-
ing differences in the mechanisms of depression underly-
ing these diseases. In addition, brain stimulation in these 
studies was aimed at decreasing pain and not depression 
symptoms; therefore it is unclear whether brain stimu-
lation would have a positive clinical effect on depression 
in fibromyalgia.
Other conditions
Finally another issue that needs to be considered is 
that, in some cases, depression in some clinical condi-
tions might be associated with changes in neural circuits 
that also are responsible for sustaining the clinical man-
ifestation of disease. For instance, hypothyroidism is an 
example of such situation. It is well known that hypo-
thyroidism is linked to behavioral disturbances, cognitive 
deficits and psychiatric illnesses122. Rizzo et al.123 studied 
cortical excitability to transcranial magnetic stimulation 
(TMS) in 10 patients with hypothyroidism, comparing 
them to 10 healthy volunteers. They found a few abnor-
malities in cortical excitability in the patients. After hor-
mone replacement therapy with thyroid hormone over a 
period of 3 to 6 months, it was seen that cortical excit-
ability parameters were back to normal. Because rTMS 
has been shown to induce hormonal changes, it needs to 
be investigated whether rTMS for depression in this con-
dition would induce hormonal changes that might not be 
necessarily beneficial.
For the clinician, the cause-effect relationship between 
medical illness and depression is often not clear: it is not 
known whether depressive symptoms are a risk factor fa-
voring the appearance of a medical ailment, or just a con-
sequence of the latter (in fact both conditions are possi-
ble). Neurostimulation techniques will act upon specific 
brain areas known to be associated with the pathophysi-
ology of depression, such as the prefrontal cortex, without 
acting upon areas that may be linked to the pathophysiol-
ogy of the concurrent clinical illness. In this case, there is 
a question of whether neurostimulation would induce an 
improvement of depression symptoms given that mech-
anisms underlying MDD might be different than those of 
secondary depression.
Neurological diseases
Depression is a common finding in patients with neu-
rological diseases: in fact, its prevalence is up to 50%, es-
pecially in chronic conditions such as dementia, epilep-
sy, migraine, multiple sclerosis, Parkinson’s disease and 
stroke. In these conditions, depressive symptoms are as-
sociated with increased burden, poor quality of life, im-
paired therapeutic response and, hence, to poor progno-
sis124-129. On the other hand, depressive symptoms associ-
ated with neurological diseases usually display a good re-
sponse to pharmacological interventions, with the same 
drugs used in MDD, although patients may experience 
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more adverse events depending on the nature of their 
neurological diagnosis130. Thus, new treatment approach-
es are still necessary in order to provide better care to this 
subset of patients. We discuss here the use of some of the 
techniques of brain stimulation for treatment of depres-
sion in neurological diseases.
Post-stroke depression
RTMS has been shown to be effective and safe in treat-
ing depression in patients with stroke. A controlled study 
compared sham and active rTMS on the left prefrontal 
cortex in patients with refractory post-stroke depression 
found that a series of ten sessions of active high frequen-
cy rTMS was associated with a significant reduction of 
depressive symptoms, with mild adverse events131. 
Parkinson’s disease
In MDD associated with Parkinson’s disease, several 
open and controlled studies have been published, show-
ing consistent improvement of depressive symptoms as 
well as motor symptoms after prefrontal stimulation132-136. 
Two randomized controlled trials showed that the effica-
cy of rTMS is similar to fluoxetine in patients with this 
condition, but with less adverse events133,135.
Epilepsy
Potential use of rTMS in epileptic patients with de-
pression has also been suggested137, although specific 
studies in this indication are still lacking, but are partic-
ularly important due to safety issues as in this case low-
frequency rTMS that has a significant anti-epileptic ef-
fect can be used and therefore a combined treatment of 
epilepsy and depression might be possible. VNS, anoth-
er related technique, has shown to be effective not only 
in reducing seizure frequency but also in improving de-
pressive symptoms in epileptic patients138. 
Similar opportunities might be applicable to tDCS. 
Because no trial with this technique has been conducted 
yet, this is another interesting area of future research es-
pecially due to the portability characteristics of tDCS.
MDD in the rehabilitation setting
Depressive disorders are common in the rehabilita-
tion settings. In fact, approximately 30 to 40% of stroke 
survivors will experience clinically significant depression 
during the first year after stroke139 and at some point fol-
lowing a stroke140,141. Over half of these patients will de-
velop major or minor depression in the acute care reha-
bilitation settings142. In fact, depression is considered to 
be the strongest predictor of quality of life in this patient 
population143,144 and is associated with reduced rehabili-
tation treatment efficacy, poor functional recovery, poor 
social outcomes, increased cognitive impairment and in-
creased mortality145.
Antidepressants, psychostimulants, counseling and 
psychotherapy are the most commonly prescribed in-
terventions. However, despite showing some beneficial 
effects146,147, pharmacological management of depression 
may be contraindicated due to their cardiovascular and 
anticholinergic adverse effects131. Some trials have dem-
onstrated that selective serotonin reuptake inhibitors are 
no more effective than placebo in treating depression 
among stroke survivors148. ECT may be an alternative for 
refractory patients; however, caution should be exercised 
in stroke patients due to the risk of provoking or aggra-
vating cognitive dysfunction.
Therefore, other safe treatment modalities are need-
ed to effectively address this common clinical condition. 
RTMS may be an alternative treatment for stroke patients 
either with refractory depression or who are unable to use 
antidepressant medications. A recent study showed that 
ten to 15 sessions of rTMS applied on the left DLPFC at 
a frequency of 10Hz, and an intensity of 110% MT was 
associated with significant reduction of depressive symp-
toms by 30% and a remission rate of 10% as compared to 
placebo intervention. Mild and few adverse effects such 
as headache were reported131-149. Another advantage of 
the use of rTMS is the improvement in executive func-
tions by rTMS150,151. Preliminary data suggests that bet-
ter responses to magnetic stimulation are obtained in pa-
tients with higher frontal volumes. For patients with se-
vere frontal atrophy, higher intensity and prolonged stim-
ulation might be required. Finally, because of the posi-
tive effects of rTMS for motor recovery and reduction 
of spasticity, it is conceivable that patients might receive 
combined treatment for these conditions, being the pa-
rameters adjusted for either mood or motor symptoms, 
for instance.
MDD and cognition
In addition to the symptoms usually observed in 
MDD, there is also change in some cognitive domains 
such as verbal memory, working memory, and selective 
attention152. Moreover, according to depression severity 
and cognitive performance, some patients present a pat-
tern of the so-called pseudodementia153,154. Also, pharma-
cological strategies in the management of MDD can re-
sult in negative effects on cognition - tricyclic antidepres-
sants, for instance, have been associated with cognitive 
impairments in attention, memory and executive func-
tion155. These adverse effects indicate the need for new 
therapeutic strategies with fewer adverse cognitive effects 
and, in this scenario, neuromodulation techniques are be-
ginning to be investigated.
Vanderhasselt et al.156 assessed attentional control and 
depressive symptoms before and after rTMS over the left 
DLPFC. The authors observed improvement in attention-
al control in responders at the first rTMS session. Fitzger-
ald et al.157 tested the antidepressant effects of high-fre-
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quency rTMS over the left DLPFC and low-frequency 
over the right DLPFC. Besides the improvement of de-
pressive symptoms in both strategies of stimulation, an 
improvement in immediate verbal memory and verbal 
fluency was also observed.
Regarding tDCS, a preliminary study by Fregni et al.158 
showed that 5 days of anodal stimulation over the left DLP-
FC did not result in deleterious effects on functions such 
as memory, attention, language and executive functions. 
Instead, an improvement in working memory was found. 
Cognitive/affective information processing is also al-
tered in MDD. Bermpohl et al.159 investigated the effect 
of rTMS over the DLPFC of depressed patients in a go/
no-go task with emotional content, finding that low-fre-
quency rTMS resulted in improved performance in the 
task when applied to the right DLPFC. Likewise, Boggio 
et al.160 investigated the effects of anodal tDCS applied 
over the left DLPFC of MDD patients during the same go/
no-go task, observing an improvement in performance 
during the tDCS session in comparison to sham or oc-
cipital stimulation. 
Such observations can also be extended to depression-
related neurological diseases, such as observed in Parkin-
son’s disease. Fregni et al.161 found that high-frequency 
rTMS applied over the left DLPFC daily for ten days re-
sulted in reduction of depressive symptoms. Boggio et 
al.162 found that this improvement extended to cognitive 
functions such as verbal fluency and executive functions. 
The same authors found that anodal tDCS (2 mA) applied 
over the left DLPFC of patients with Parkinson’s disease 
resulted in an improvement in working memory task163. 
With respect to DBS, some studies have shown 
that this technique is also associated with gains in 
memory164,165. Parameters such as amplitude and pulse 
width are associated with improvement in cognitive 
performance166. On the other hand, some authors have 
shown negative effects related to functions such as ver-
bal fluency and attention165,167. 
In addition, two key factors for assessing the cog-
nitive effects of neuromodulation techniques used as 
tools for the treatment of depression are: 1) neural net-
work underlying this disorder integrates structures such 
as prefrontal cortex, amygdala, cingulate and thalamus, 
and 2) cascading effects resulting from stimulation (top-
down and bottom-up regulation according to the type of 
neuromodulation)168. 
Thus, it was observed that from the point of view of 
cognitive functions, neuromodulation techniques appear 
as promising tools associated with low cognitive adverse 
effects and might also improve cognitive functions. New 
studies are mandatory to disentangle the effects of each 
brain stimulation technique for each specific cognitive 
domain. 
Clinical research in brain stimulation
To date, brain stimulation trials have produced mixed 
results. Despite the difficulties inherent in the techni-
cal aspects of the intervention (i.e., site of stimulation, 
amount of energy delivered, validation in animal stud-
ies, lack of deep understanding in its mechanisms of ac-
tion), the methodology of brain stimulation trials also fac-
es important issues that might preclude the achievement 
of significant results.
In a recent review, Brunoni and Fregni83 reviewed 31 
brain stimulation trials published from 2002-2008 and 
identified some issues that could be arranged in three 
main topics:
[1] Issues inherent to small, exploratory studies - The 
small sample size of almost all trials could have produced 
false negative results (due to underpower) as well as false 
positive results (due to multiple hypothesis testing). Such 
caveats could be minimized in future trials by determin-
ing a priori the main hypothesis of the study and, conse-
quently, by estimating the sample size necessary to prove 
the main hypothesis. For instance, the authors identified 
that only 20% of studies estimating sample size had neg-
ative results, while 33% not estimating had negative re-
sults. Moreover, the authors observed the statistics of the 
studies are very sophisticated, which is a natural alterna-
tive to overcome the lack of power. On the other hand, 
the use of complex models can violate statistical assump-
tions and thus produce false findings.
[2] Issues inherent to MDD trials - Here the prob-
lems identified were of construct validity and reliabili-
ty of the instruments used to diagnose and quantify de-
pression. An important topic is the definition of treat-
ment resistant depression - 30% provided no definition, 
55% defined it as when at least one antidepressant trial in 
adequate dose and duration failed, and 15% required at 
least two failed trials. In addition, the issue of using cat-
egorical (remission) or continuous (score change) out-
comes is under debate, both approaches have their pros 
and cons: categorical outcomes produces more clinical-
ly meaningful results but generally demands larger sam-
ple sizes; on the other hand, continuous outcomes pro-
duces more statistically meaningful results but demands 
smaller sample sizes.
[3] Issues specific no NIBS trials - A specific issue is 
blinding. In rTMS trials, the most common methods of 
blinding do not guarantee double-blinding, an issue that 
might bias results in two ways: by increasing response in 
the active group (by increased staff care and positive en-
forcement) and decreasing it in control group. Also, some 
authors raised the issue that angled coil - a method used 
in sham groups of numerous rTMS trials - might still in-
duce cortical changes thus not being a “real” sham. On 
the other hand, a recent meta-analysis of sham respons-
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es showed angled vs. sham coils produce similar effect 
sizes169. In tDCS trails, blinding vulnerability is a minor 
problem as; accordingly to the set of parameters specified, 
both groups will suffer no adverse events, thus providing 
a more reliable blinding. Another issue is the target sam-
ple of brain stimulation studies - focusing on treatment 
resistant depression per se favors smaller effect sizes. 
Therefore, future directions in brain stimulation re-
search could be: [1] to use alternative designs - after regu-
latory approval of some brain stimulation techniques, the 
use of naturalistic, follow-up studies can help to find pre-
dictors associated with better outcomes, such as age, gen-
der, degree of refractoriness, use of concomitant medica-
tions and comorbid psychiatric diagnostics as well as en-
dophenotypes - for instance, neuroimaging, genetic poly-
morphisms, BDNF baseline serum levels and neuropsy-
chological and psychophysiological testing; [2] to recruit 
alternative populations - since rTMS is a safe, non-inva-
sive technique with at least comparable effect sizes with 
antidepressant drugs, its use could be extended in pa-
tients not able or not ideally indicated to use medica-
tions, for example, breast-feeding women, elderly patients 
with polypharmacy, patients taking drugs with unfavor-
able pharmakocinetics (e.g. chemotherapy, immunosup-
pressant drugs) or even those not wanting to take pills; 
[3] to set a collaborative network - since most clinical 
studies in brain stimulation are developed in university 
setting with limited, public funding, the design of large 
trials is often unfeasible. An alternative would be to set 
an international collaborative network in which data are 
gathered from different centers - such approach could be 
used to do multicenter trials as well as to build a data-
bank to perform exploratory, post-hoc analyses and iden-
tify predictors of treatment- if blood samples are collect-
ed and stored, biochemical endophenotypes could also 
be researched. Finally, such network would be especially 
important for safety issues as to identify the prevalence 
of side effects associated with brain stimulation; [4] to 
design head-to-head comparisons against pharmacolog-
ical treatments - although the effect size of rTMS in re-
cent meta-analyses is comparable to the effect size of an-
tidepressant trials, it is not straightforward to claim such 
approaches have similar efficacy, as pharmacological and 
non-pharmacological trials are methodologically dif-
ferent. Therefore, direct head-to-head comparisons are 
necessary to evaluate this issue - along these lines, a re-
cent trial compared low-frequency right-sided rTMS (20 
sessions)+placebo vs. venlafaxine ER (mean dose 256mg/
day)+sham rTMS for TRD and found both interventions 
to have similar efficacy in ameliorating depressive symp-
toms68; [5] to research optimal parameters of stimulation: 
the optimal number of applications (10 vs. 20 sessions), 
train frequency (low frequency, 5 Hz, 10 Hz, 20 Hz high-
frequency), session parameters (low-frequency right-sid-
ed vs. high-frequency left-sided, concomitant application, 
potency in relation to motor threshold) and site of appli-
cation (direct measurement for targeting DLPFC vs. neu-
ronavegation). On the other hand, the amount of vari-
ables to combine would require several clinical trials - 
an alternative would be to use adaptive designs, starting 
with several combinations and dropping weaker treat-
ments during the trial.
conclusIons 
In the current review, we convened a group of experts 
in the field to review and synthesize the available evidence 
for using neuromodulation interventions in major depres-
sive disorder - a chronic, relapsing disorder that is associ-
ated with significant prevalence and morbidity that also 
accompanies many non-psychiatric conditions. In agree-
ment with the literature, we found that ECT and rTMS 
are viable alternatives for treating the acute depressive 
episode: ECT has been widely recognized for the treat-
ment of refractory and/or severe depression and is some-
what limited in other conditions due to adverse cogni-
tive events and difficulty of using it in clinical practice 
(e.g. anesthesia, an accompanying person is needed, post-
ECT amnesia); while rTMS might have a broader range 
of use as currently established by some guidelines (e.g., 
the FDA), however more studies are needed as the opti-
mal parameters have not been established. DBS, VNS and 
tDCS are possible strategies for major depressive disor-
der that demand more controlled trials in order to assess 
their role in the realm of depressive disorders - howev-
er, while the invasiveness of DBS and VNS will natural-
ly limit their use to the most severe spectrum of depres-
sive disorder, the “user-friendly” approach of tDCS (i.e., 
low cost, absence of side effects, portable device, can be 
built to be operated by the patient or relative) is a prom-
ising alternative to treat a wide range of depressed pa-
tients, if such technique is proven to be effective in the 
near future. Along these lines, novel, non-invasive brain 
stimulation modalities (such as rTMS and tDCS) could 
be better explored when managing depressive symptoms 
in non-psychiatric disorders, as hazardous pharmacoki-
netic interactions are possible when antidepressants are 
associated with other drugs, and also because these nov-
el treatments might also have positive “cognitive side ef-
fects”. In summary, while to date only ECT has robust ef-
ficacy for major depressive disorder, the continuous re-
search of novel neuromodulation techniques is showing 
promising results and therefore the attending physician 
should consider them as alternatives when treating a de-
pressed patient. 
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